Susana Conde-Ceide

USPTO Granted Patents = 19 (Patent Applications = 10)

CIPO Patents = 7 (Patent Applications = 4)

EPO Patents = 8 (Patent Applications = 18)

Average Co-Inventor Count = 6.2

ph-index = 3

Forward Citations = 24(Granted Patents)

Company Filing History:

9 out of 2,078

Janssen Pharmaceutica Nv

patents

9 out of 1,153

Vanderbilt University

patents

1 out of 1

Beerse Pharmaceutica Nv

patent

Years Active: 2013-2020

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10668065 - 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors (2020-06-02),

2. 10519162 - 6,7-dihydropyrazolo[1,5-α]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors (2019-12-31),

3. 10220032 - 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors (2019-03-05),

4. 10017514 - [object Object] (2018-07-10),

5. 10005785 - Substituted 6,7-dihydropyrazolo[1,5-a] pyrazines as negative allosteric modulators of mGlUR2 receptors (2018-06-26),

6. 9550784 - Inhibitors of phosphodiesterase 10 enzyme (2017-01-24),

7. 9255103 - Substituted pyrazolo[1,5-a]pyrazines as mGluR5 receptor modulators (2016-02-09),

8. 9090632 - Bicyclic oxazole and thiazole compounds and their use as allosteric modulators of mGluR5 receptors (2015-07-28),

9. 9040707 - Bicyclic thiazoles as allosteric modulators of mGluR5 receptors (2015-05-26),

10. 9029366 - Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mGluR5 receptors (2015-05-12),

11. 8901125 - Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mGluR5 receptors (2014-12-02),

12. 8865725 - Substituted imidazopyrimidin-5(6H)-ones as allosteric modulators of MGLUR5 receptors (2014-10-21),

13. 8859543 - Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases (2014-10-14),

14. 8853237 - Naphthyridinone analogs as mGluR5 positive allosteric modulators (2014-10-07),

15. 8716282 - Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors (2014-05-06),

Title: Innovations of Susana Conde-Ceide: Pioneering Research in Pharmacology

Introduction

Susana Conde-Ceide is a notable inventor based in Toledo, Spain, recognized for her significant contributions in the field of pharmacology. With an impressive portfolio of 19 patents, her work is pivotal in advancing medical science and therapeutic applications.

Latest Patents

Among her latest innovations are the 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one compounds, which serve as negative allosteric modulators of the metabotropic glutamate receptor subtype 2 (mGluR2). This invention includes a range of novel derivatives that exhibit potential in treating various disorders linked to the mGluR2 receptor pathways. These compounds not only enhance therapeutic efficacy but also open avenues for new pharmaceutical compositions aimed at preventing or treating specific health conditions.

Career Highlights

Susana has built an impressive career through her affiliations with leading organizations, including Janssen Pharmaceutica and Vanderbilt University. Her research endeavors have substantially contributed to the pharmaceutical industry by focusing on innovative drug development and therapeutic strategies.

Collaborations

Throughout her career, Susana has collaborated with esteemed professionals such as José Manuel Bartolomé-Nebreda and Michiel Luc Maria Van Gool. These partnerships have enabled her to leverage interdisciplinary expertise, fostering advancements in her research initiatives.

Conclusion

In summary, Susana Conde-Ceide exemplifies the role of inventors in driving pharmaceutical innovation. Her substantial contributions through her patents not only reflect her expertise but also her commitment to enhancing healthcare solutions. As her work continues to evolve, it promises to further impact the fields of pharmacology and therapeutic development.

This text is generated by artificial intelligence and may not be accurate.